New antibody drug takes aim at relapsed leukemia
NCT ID NCT07109219
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests a new drug called AZD4512 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. The drug is an antibody-drug conjugate that delivers a toxic payload directly to cancer cells. The trial has two parts: first, finding a safe dose, then checking how well it works. About 83 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGDuarte, California, 91010, United States
-
Research Site
WITHDRAWNJacksonville, Florida, 32224, United States
-
Research Site
RECRUITINGChicago, Illinois, 60611, United States
-
Research Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
RECRUITINGFranklin, Tennessee, 37067, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
-
Research Site
RECRUITINGToronto, Ontario, M5G 1X6, Canada
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510515, China
-
Research Site
NOT_YET_RECRUITINGTianjin, 301600, China
-
Research Site
RECRUITINGBunkyō City, 113-8677, Japan
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 06591, South Korea
-
Research Site
RECRUITINGSeoul, 3722, South Korea
-
Research Site
NOT_YET_RECRUITINGBadalona(Barcelona), 08916, Spain
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGSalamanca, 37007, Spain
-
Research Site
RECRUITINGSantander, 39008, Spain
-
Research Site
WITHDRAWNValencia, 46026, Spain
-
Research Site
RECRUITINGTaichung, 40705, Taiwan
-
Research Site
RECRUITINGTaipei, 106, Taiwan
-
Research Site
RECRUITINGBloomsbury, W1T 7HA, United Kingdom
-
Research Site
RECRUITINGManchester, M20 4BX, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD4512, an antibody-drug conjugate that targets CD22 on cancer cells
What this could lead to
If it works, this could offer a new treatment option for people with B-cell acute lymphoblastic leukemia that has come back or not responded to other therapies.
What could go wrong
This is an early-phase trial with only 83 participants, so it may not show strong enough results or could have unexpected side effects. The drug is still experimental.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.